Actinium Pharmaceuticals to Present Early Phase 1 Data for ATNM-400 in Prostate Cancer at EANM

• Actinium Pharmaceuticals will present early Phase 1 results for prostate cancer therapy ATNM-400 on October 19, 2026, at EANM in Vienna.
• Initial clinical data support advancing the non-PSMA-targeted radiotherapy for metastatic castration-resistant prostate cancer.
• ATNM-400 targets patients with low or absent PSMA expression, including those whose disease resists PSMA-directed therapies.
• The ongoing first-in-human trial evaluates safety and drug distribution to guide dosing of the actinium-225 therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150830PR_NEWS_USPR_____NY72874) on October 15, 2026, and is solely responsible for the information contained therein.